PD-1 inhibitor plus concurrent chemoradiotherapy for high-risk locally advanced cervical cancer-Reference-Cited by-同舟云学术

PD-1 inhibitor plus concurrent chemoradiotherapy for high-risk locally advanced cervical cancer

Published:2024-06-03 Issue:20 Volume:20 Page:1415-1426
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

Wang Cong¹^ORCID,Liu Lijun²,Li Xia¹,Lei Jia¹,Li Yiqian¹,Shen Zhibo¹,Shi Huirong³,Cheng Yan¹^ORCID

Affiliation:

1. Department of Gynecological Radiation Oncology, Zhengzhou University First Affiliated Hospital, No 1. Jianshe Road, Zhengzhou, 450000, China

2. Department of Rheumatology, Zhengzhou University First Affiliated Hospital, No 1. Jianshe Road, Zhengzhou, 450000, China

3. Department of Gynecology, Zhengzhou University First Affiliated Hospital, No 1. Jianshe Road, Zhengzhou, 450000, China

Funder

the key Research and development and promotion Special project (Science and Technology Research) of Henan Provincial Science and Technology Department in 2023

the Key scientific Research Project of Henan Provincial Colleges and Universities in 2022

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/14796694.2024.2342241

Reference62 articles.

1. Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. Cervical cancer

3. Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology

4. The Preliminary Results of 3-Dimensional Printed Individual Template Assisted 192Ir High-Dose Rate Interstitial Brachytherapy for Central Recurrent Gynecologic Cancer

5. Prognostic Performance of the 2018 International Federation of Gynecology and Obstetrics Cervical Cancer Staging Guidelines